Quantcast
Published On: Fri, Mar 21st, 2014

Study brings renewed hope for Stimuvax as a potential lung cancer vaccine

Researchers at UC Davis have found that the investigational cancer vaccine tecemotide, when administered with the chemotherapeutic cisplatin, boosted immune response and reduced the number of tumors in mice with lung cancer. The study also found that radiation treatments did not significantly impair the immune response. The paper was published on March 10 in the journal Cancer Immunology Research, an American Association for Cancer Research (AACR) publication.

Michael DeGregorio Image/UC Davis

Michael DeGregorio
Image/UC Davis

Though tecemotide, also known as Stimuvax, has shown great potential at times, the recent Phase III trial found no overall survival benefit for patients with non-small cell lung cancer (NSCLC). However, further analysis showed one group of patients, who received concurrent chemotherapy and radiation followed by tecemotide, did benefit from the vaccine. As a result, tecemotide’s manufacturer, Merck KGaA, is sponsoring additional post-clinical animal and human studies, so far with good results.

“There aren’t any good options for patients with inoperable stage III lung cancer following mainline chemotherapies,” said UC Davis Professor of Medicine and lead author Michael DeGregorio. “We are looking at tecemotide as a potential maintenance therapy to prolong survival and improve quality of life.”

Tecemotide activates an immune response by targeting the protein MUC1, which is often overexpressed in lung, breast, prostate and other cancers. The vaccine stimulates production of interferon gamma and MUC1-targeted killer T-lymphocytes, which seek out and destroy MUC1 cancer cells.

Read the rest of the UC Davis news release

On the DISPATCH: Headlines  Local  Opinion

Subscribe to Weekly Newsletter

* indicates required
/ ( mm / dd ) [ALL INFO CONFIDENTIAL]

About the Author

- The generic Dispatch designation, used primarily for press releases or syndicated content, but may be used for guest author requesting a generic nomenclature

Tags

Leave a comment

XHTML: You can use these html tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>

Sign up for our Weekly Newsletter



Recent Posts

How is a Car Accident Claim Filed? And Other Questions A Lawyer Can Answer

January 27, 2023, Comments Off on How is a Car Accident Claim Filed? And Other Questions A Lawyer Can Answer

The Best Uses for a Home Equity Loan

January 24, 2023, Comments Off on The Best Uses for a Home Equity Loan

Top 8 Reasons to Get an Outdoor Kitchen

January 22, 2023, Comments Off on Top 8 Reasons to Get an Outdoor Kitchen

How is a Christian Wedding Invite Different than a Secular Wedding Invite

January 16, 2023, Comments Off on How is a Christian Wedding Invite Different than a Secular Wedding Invite

Fun and Unusual Ways to Encourage Kids to Stay Healthy

January 12, 2023, Comments Off on Fun and Unusual Ways to Encourage Kids to Stay Healthy

Health Carousel Honors Dr Franklin Shaffer with the DAISY Lifetime Achievement Award

January 12, 2023, Comments Off on Health Carousel Honors Dr Franklin Shaffer with the DAISY Lifetime Achievement Award

5 Reasons Why Truck Accident Claims Are More Complicated

January 10, 2023, Comments Off on 5 Reasons Why Truck Accident Claims Are More Complicated
nft blockchain

What You Need to Know About NFTs as We Enter 2023

January 7, 2023, Comments Off on What You Need to Know About NFTs as We Enter 2023

Categories

Archives